Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older

Key Points

• To understand the mutation spectrum in elderly patients with acute myeloid leukemia and its clinical implications.
• Analyzed genetic mutations in intensively treated patients aged 75 years or older.
• Part of the AMLCG-1999 trial (NCT00266136).
• Identified mutations as novel markers for chemorefractory disease.
• Found correlations between specific mutations and inferior prognosis.